Coronary-artery revascularization before elective major vascular surgery
2005; Elsevier BV; Volume: 14; Issue: 4 Linguagem: Inglês
10.1016/j.accreview.2005.03.013
ISSN1879-2065
AutoresEdward O. McFalls, Herbert B. Ward, Thomas Moritz,
Tópico(s)Pain Management and Treatment
ResumoEtiology and pathophysiology of chronic internal disease was unknown until last days. This article challenges that two clinical trials have discovered the origin of chronic prostate diseases.The hypothesis of the chronic internal diseases cause due to pathological activity of capillaries with emerging micro-focus of hypothermia, a continuous trigger for disease development in any affected organ, was declared in the US patent “Therapeutic Device and Method”, i.e. thermobalancing therapy (TT) and therapeutic device. Two clinical trials before and 6 months after TT for chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) and benign prostatic hyperplasia (BPH) with the device, namely Dr. Allen's therapeutic device (DATD) confirmed the effectiveness of TT. This device was used as mono-therapy for 124 patients with BPH and 45 men with CP/CPPS.Compared to controls, the TT groups showed significant improvements from baseline to endpoint. TT in men with BPH decreased urinary symptoms and PV, increased Qmax and improved quality of life index (QoL). At the same time, another clinical trial on TT in men with CP/CPPS has demonstrated decrease of pain score and PV mL, improvement of QoL and increase of Qmax mL/sec.The long-term application of the source of emitted body heat with DATD, i.e. TT, to the projection of affected prostate removes “micro-focus” of hypothermia at the capillary level that improves blood circulation in the organ and its function. Thus this article shows that the underlying cause for different chronic internal diseases, such as BPH and CP/CPPS is the same and is positioned at the microvascular level. More studies with thermobalancing therapy needed.
Referência(s)